PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23658559-9	2013	A small number of lines lacking a BRAF mutation were sensitive to CI-1040 but resistant to vemurafenib.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	66-73	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	34-38	
19018267-13	2008	Therefore, ovarian cancer patients with KRAS or BRAF mutations may benefit from CI-1040 treatment.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	80-87	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	48-52	
17911174-0	2007	Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	76-83	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	151-155	
17911174-9	2007	CONCLUSIONS: We for the first time demonstrated potent inhibitory effects of a MEK inhibitor, CI-1040, on thyroid cancer cells, some of which, particularly cell proliferation and tumor growth, seemed to be BRAF mutation or RAS mutation selective.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	94-101	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	206-210